UBS has initiated coverage of Sight Sciences (SGHT) with a Buy recommendation, projecting a 44.28% upside based on an average one-year price target of $5.57 per share. The company anticipates a 51.68% increase in annual revenue, reaching $121 million, despite a projected non-GAAP EPS of -1.00. Institutional ownership has risen, with 182 funds reporting positions, although some major shareholders, including UBS and Bank of America, have reduced their stakes significantly.
Sight Sciences, Inc. is an ophthalmic technology company specializing in surgical and non-surgical solutions for common eye diseases. Its Surgical Glaucoma segment features the OMNI Surgical System and SION Surgical Instrument, while the Dry Eye segment offers the TearCare System, a wearable technology targeting meibomian gland dysfunction.
UBS has initiated coverage of Sight Sciences Inc. (NASDAQ: SGHT) with a Buy rating and a $5.50 price target, highlighting strong sales growth potential by 2026. The company is shifting focus from its OMNI glaucoma solution to the TearCare dry eye treatment, targeting a $2.5 billion market. Despite recent revenue challenges, the analyst anticipates significant sales growth as TearCare transitions to a reimbursed model, with 1,000 trained surgeons poised for adoption.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.